SANOFI-ADR (SNY) Fundamental Analysis & Valuation

NASDAQ:SNY • US80105N1054

44.35 USD
-0.2 (-0.45%)
At close: Mar 9, 2026
44.43 USD
+0.08 (+0.18%)
Pre-Market: 3/10/2026, 4:57:45 AM

This SNY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 193 industry peers in the Pharmaceuticals industry. While SNY has a great profitability rating, there are some minor concerns on its financial health. SNY is valued quite cheap, while showing a decent growth score. This is a good combination! Finally SNY also has an excellent dividend rating. These ratings could make SNY a good candidate for value and dividend investing.


Dividend Valuation Growth Profitability Health

8

1. SNY Profitability Analysis

1.1 Basic Checks

  • In the past year SNY was profitable.
  • SNY had a positive operating cash flow in the past year.
  • In the past 5 years SNY has always been profitable.
  • SNY had a positive operating cash flow in each of the past 5 years.
SNY Yearly Net Income VS EBIT VS OCF VS FCFSNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • The Return On Assets of SNY (9.85%) is better than 91.19% of its industry peers.
  • SNY's Return On Equity of 17.49% is amongst the best of the industry. SNY outperforms 89.12% of its industry peers.
  • SNY has a Return On Invested Capital of 13.76%. This is amongst the best in the industry. SNY outperforms 93.78% of its industry peers.
  • SNY had an Average Return On Invested Capital over the past 3 years of 7.41%. This is significantly below the industry average of 13.09%.
  • The last Return On Invested Capital (13.76%) for SNY is above the 3 year average (7.41%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.85%
ROE 17.49%
ROIC 13.76%
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
SNY Yearly ROA, ROE, ROICSNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • SNY's Profit Margin of 17.71% is amongst the best of the industry. SNY outperforms 91.19% of its industry peers.
  • In the last couple of years the Profit Margin of SNY has declined.
  • SNY has a better Operating Margin (23.28%) than 90.16% of its industry peers.
  • In the last couple of years the Operating Margin of SNY has grown nicely.
  • SNY's Gross Margin of 72.55% is fine compared to the rest of the industry. SNY outperforms 79.27% of its industry peers.
  • In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
Industry RankSector Rank
OM 23.28%
PM (TTM) 17.71%
GM 72.55%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
SNY Yearly Profit, Operating, Gross MarginsSNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. SNY Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SNY is still creating some value.
  • The number of shares outstanding for SNY has been reduced compared to 1 year ago.
  • Compared to 5 years ago, SNY has less shares outstanding
  • The debt/assets ratio for SNY is higher compared to a year ago.
SNY Yearly Shares OutstandingSNY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
SNY Yearly Total Debt VS Total AssetsSNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • The Debt to FCF ratio of SNY is 1.86, which is an excellent value as it means it would take SNY, only 1.86 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of SNY (1.86) is better than 95.34% of its industry peers.
  • A Debt/Equity ratio of 0.22 indicates that SNY is not too dependend on debt financing.
  • SNY has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: SNY outperforms 43.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 1.86
Altman-Z N/A
ROIC/WACC1.75
WACC7.85%
SNY Yearly LT Debt VS Equity VS FCFSNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.09 indicates that SNY should not have too much problems paying its short term obligations.
  • SNY has a worse Current ratio (1.09) than 80.31% of its industry peers.
  • SNY has a Quick Ratio of 1.09. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
  • SNY's Quick ratio of 1.09 is on the low side compared to the rest of the industry. SNY is outperformed by 74.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
SNY Yearly Current Assets VS Current LiabilitesSNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

4

3. SNY Growth Analysis

3.1 Past

  • SNY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.82%.
  • The Earnings Per Share has been growing slightly by 5.58% on average over the past years.
  • Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 5.29% in the last year.
  • The Revenue has been growing slightly by 4.57% on average over the past years.
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%

3.2 Future

  • Based on estimates for the next years, SNY will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.49% on average per year.
  • The Revenue is expected to grow by 5.29% on average over the next years.
EPS Next Y8.41%
EPS Next 2Y6.95%
EPS Next 3Y8.43%
EPS Next 5Y8.49%
Revenue Next Year6.58%
Revenue Next 2Y6.19%
Revenue Next 3Y5.8%
Revenue Next 5Y5.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SNY Yearly Revenue VS EstimatesSNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B 50B
SNY Yearly EPS VS EstimatesSNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

7

4. SNY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.73, which indicates a very decent valuation of SNY.
  • 91.19% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
  • SNY is valuated cheaply when we compare the Price/Earnings ratio to 26.46, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 8.96 indicates a reasonable valuation of SNY.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 90.16% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (24.65), we can say SNY is valued rather cheaply.
Industry RankSector Rank
PE 9.73
Fwd PE 8.96
SNY Price Earnings VS Forward Price EarningsSNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 93.26% of the companies in the same industry are more expensive than SNY, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.49
EV/EBITDA N/A
SNY Per share dataSNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • SNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)1.16
PEG (5Y)1.74
EPS Next 2Y6.95%
EPS Next 3Y8.43%

7

5. SNY Dividend Analysis

5.1 Amount

  • SNY has a Yearly Dividend Yield of 5.30%, which is a nice return.
  • Compared to an average industry Dividend Yield of 0.70, SNY pays a better dividend. On top of this SNY pays more dividend than 97.41% of the companies listed in the same industry.
  • SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 5.3%

5.2 History

  • The dividend of SNY has a limited annual growth rate of 4.30%.
  • SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
SNY Yearly Dividends per shareSNY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

  • The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2Y6.95%
EPS Next 3Y8.43%
SNY Yearly Income VS Free CF VS DividendSNY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

SNY Fundamentals: All Metrics, Ratios and Statistics

SANOFI-ADR

NASDAQ:SNY (3/9/2026, 8:00:02 PM)

Premarket: 44.43 +0.08 (+0.18%)

44.35

-0.2 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29
Earnings (Next)04-23
Inst Owners46.23%
Inst Owner Change-1.94%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap107.12B
Revenue(TTM)70.49B
Net Income(TTM)12.49B
Analysts76
Price Target57.52 (29.7%)
Short Float %0.37%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield 5.3%
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DPN/A
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.22%
Min EPS beat(2)4.58%
Max EPS beat(2)5.86%
EPS beat(4)3
Avg EPS beat(4)3.54%
Min EPS beat(4)-2.29%
Max EPS beat(4)6.02%
EPS beat(8)6
Avg EPS beat(8)4.07%
EPS beat(12)8
Avg EPS beat(12)3.12%
EPS beat(16)11
Avg EPS beat(16)3.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.69%
Min Revenue beat(2)-2.08%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-1.33%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)-0.63%
Revenue beat(8)2
Avg Revenue beat(8)-0.61%
Revenue beat(12)2
Avg Revenue beat(12)-1.44%
Revenue beat(16)6
Avg Revenue beat(16)14.04%
PT rev (1m)-2.24%
PT rev (3m)-7.57%
EPS NQ rev (1m)0.19%
EPS NQ rev (3m)6.49%
EPS NY rev (1m)0.44%
EPS NY rev (3m)-0.61%
Revenue NQ rev (1m)-0.6%
Revenue NQ rev (3m)-1.7%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)-0.4%
Valuation
Industry RankSector Rank
PE 9.73
Fwd PE 8.96
P/S 1.32
P/FCF 8.49
P/OCF 8.49
P/B 1.3
P/tB 24.3
EV/EBITDA N/A
EPS(TTM)4.56
EY10.28%
EPS(NY)4.95
Fwd EY11.16%
FCF(TTM)5.22
FCFY11.78%
OCF(TTM)5.22
OCFY11.78%
SpS33.72
BVpS34.15
TBVpS1.83
PEG (NY)1.16
PEG (5Y)1.74
Graham Number59.19
Profitability
Industry RankSector Rank
ROA 9.85%
ROE 17.49%
ROCE 16.67%
ROIC 13.76%
ROICexc 14.92%
ROICexgc 58.3%
OM 23.28%
PM (TTM) 17.71%
GM 72.55%
FCFM 15.49%
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
ROICexc(3y)8.06%
ROICexc(5y)8.26%
ROICexgc(3y)31.82%
ROICexgc(5y)35.77%
ROCE(3y)8.99%
ROCE(5y)9.04%
ROICexgc growth 3Y-8.07%
ROICexgc growth 5Y1.04%
ROICexc growth 3Y-0.36%
ROICexc growth 5Y3.93%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 1.86
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 87.43%
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z N/A
F-Score5
WACC7.85%
ROIC/WACC1.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)127.25%
Profit Quality(5y)123.49%
High Growth Momentum
Growth
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
EPS Next Y8.41%
EPS Next 2Y6.95%
EPS Next 3Y8.43%
EPS Next 5Y8.49%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%
Revenue Next Year6.58%
Revenue Next 2Y6.19%
Revenue Next 3Y5.8%
Revenue Next 5Y5.29%
EBIT growth 1Y7.73%
EBIT growth 3Y0.11%
EBIT growth 5Y6.43%
EBIT Next Year28.69%
EBIT Next 3Y14.49%
EBIT Next 5Y9.74%
FCF growth 1Y85.47%
FCF growth 3Y9.46%
FCF growth 5Y15.4%
OCF growth 1Y20.22%
OCF growth 3Y1.22%
OCF growth 5Y8.03%

SANOFI-ADR / SNY FAQ

What is the fundamental rating for SNY stock?

ChartMill assigns a fundamental rating of 6 / 10 to SNY.


Can you provide the valuation status for SANOFI-ADR?

ChartMill assigns a valuation rating of 7 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.


How profitable is SANOFI-ADR (SNY) stock?

SANOFI-ADR (SNY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of SANOFI-ADR (SNY) stock?

The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 9.73 and the Price/Book (PB) ratio is 1.3.